Cytogenetics and genetics of human cancer: Methods and accomplishments

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 102-126

  Sandberg, Avery A ^a   Meloni Ehrig, Aurelia M ^b  

^a Quest Diagnostics Nichols Institute ^*  (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE TUMOR; CANCER GENETICS; CARCINOGENESIS; CARCINOMA; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; GENOMICS; HISTORY; HUMAN; LEUKEMIA; LYMPHOMA; METHODOLOGY; MUTATION; PRIORITY JOURNAL; REVIEW; SOFT TISSUE TUMOR; SOLID TUMOR;

CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; GENOME, HUMAN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MODELS, GENETIC; NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 78649996822     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.10.004     Document Type: Review

References (165)

1. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer [Internet]. Updated quarterly (Feb., May, Aug., Nov.). Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman.
2. Sandberg A.A. The chromosomes in human cancer and leukemia 1990, Elsevier, New York. 2nd ed.
3. Sandberg A.A., Koepf G.F., Crosswhite L.H., Hauschka T.S. The chromosome constitution of human marrow in various developmental and blood disorders. Am J Hum Genet 1960, 12:231-249.
4. Sandberg A.A., Ishihara T., Miwa T., Hauschka T.S. The in vivo chromosome constitution of marrow from 34 human leukemias and 60 nonleukemic controls. Cancer Res 1961, 21:678-689.
5. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
6. Tjio J.H., Levan A. The chromosome number of man. Hereditas 1956, 42:1-6.
7. The principles of clinical cytogenetics 2005, Humana Press, Totowa, NJ. 2nd ed. S.L. Gersen, M.B. Keagle (Eds.).
8. Sandberg A.A., Chen Z. Cytogenetic analysis. Methods Mol Med 2001, 55:3-18.
9. Bridge J.A., Sandberg A.A. Cytogenetic and molecular genetic techniques as adjunctive approaches in the diagnosis of bone and soft tissue tumors. Skeletal Radiol 2000, 29:249-258.
10. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: gastrointestinal stromal tumors. Cancer Genet Cytogenet 2002, 135:1-22. [Erratum in: Cancer Genet Cytogenet 2002;137:156].
11. Burkhardt L., Grob T.J., Hermann I., Burandt E., Choschzick M., Jänicke F., et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2010, 123:757-765.
12. Bell E., Chen L., Liu T., Marshall G.M., Lunec J., Tweddle D.A. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010, 293:144-157.
13. Trujillo J.M., Ahearn M.J., Cork A. General implications of chromosomal alterations in human leukemia. Hum Pathol 1974, 5:675-686.
14. Hart J.S. Chromosome abnormalities in human neoplasia. Cancer Treat Rev 1983, 10:173-183.
15. Zang K.D., Singer H. Chromosomal constitution of meningiomas. Nature 1967, 216:84-85.
16. Caspersson T., Zech L., Johansson C. Analysis of human metaphase chromosome set by aid of DNA-binding fluorescent agents. Exp Cell Res 1970, 62:490-492.
17. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971, 2(7731):971-972.
18. Summer A.T., Evans H.J., Buckland R.A. New techniques for distinguishing between human chromosomes. Nature (New Biol) 1971, 232:31-32.
19. Drets M.E., Shaw M.W. Specific banding patterns of human chromosome. Proc Natl Acad Sci U S A 1971, 68:2073-2077.
20. Nishio J., Reith J.D., Ogose A., Maale G., Neff J.R., Bridge J.A. Cytogenetic findings in clear cell chondrosarcoma. Cancer Genet Cytogenet 2005, 162:74-77.
21. Pinkel D., Straume T., Gray J.W. Cytogenetic analysis using quantitative high sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A 1986, 83:2934-2938.
22. Cremer T., Lichter P., Borden J., Ward D.C., Manuelidis L. Detection of chromosome aberrations in metaphase and interphase cells by in situ hybridization using chromosome-specific library probes. Hum Genet 1988, 80:235-246.
23. Ried T., Baldini A., Rand T.C., Ward D.C. Simultaneous visualization of seven different DNA probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy. Proc Natl Acad Sci U S A 1992, 89:1388-1392.
24. Schröck E., Padilla-Nash H. Spectral karyotyping and multicolor fluorescence in situ hybridization reveal new tumor-specific chromosomal aberrations. Semin Hematol 2000, 37:334-347.
25. Kearney L. Multiplex-FISH (M-FISH): technique, developments and applications. Cytogenet Genome Res 2006, 114:189-198.
26. Schröck E., du Manoir S., Veldman T., Schoell B., Wienberg J., Ferguson-Smith M.A., et al. Multicolor spectral karyotyping of human chromosomes. Science 1996, 273:494-497.
27. Speicher M.R., Ballard S.G., Ward D.E. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996, 12:368-375.
28. Wang N. Methodologies in cancer cytogenetics and molecular cytogenetics. Am J Med Genet 2002, 115:118-124.
29. Jarosova M., Takacova S., Holzerova M., Priwitzerova M., Divoka M., Lakoma I., et al. Cryptic MLL-AF10 fusion caused by insertion of duplicated 5′ part of MLL into 10p12 in acute leukemia: a case report. Cancer Genet Cytogenet 2005, 162:179-182.
30. Melicherčíková J., Březinová J., Zemanová Z., Čermák J., Michalová K. Molecular cytogenetic analysis of complex karyotypes with derivative chromosome der(1)t(1;5) found in two patients with myeloid leukemia. Cancer Genet Cytogenet 2007, 176:150-155.
31. Pollack J.R., Perou C.M., Alizadeh A.A., Eisen M.B., Pergamenschikov A., Williams C.F., et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999, 23:41-46.
32. Pinkel D., Segraves R., Sudar D., Clark S., Poole I., Kowbel D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998, 20:207-211.
33. Helou K., Padilla-Nash H., Wangsa D., Karlsson E., Österberg L., Karlsson P., et al. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 2006, 170:1-8.
34. Balsara B.R., Pei J., Testa J.R. Comparative genomic hybridization analysis. Methods Mol Med 2002, 68:45-57.
35. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821.
36. du Manoir S., Speicher M.R., Joos S., Schröck E., Popp S., Döhner H., et al. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 1993, 90:590-610.
37. Solinas-Toldo S., Lampel S., Stilgenbauer S., Nickolenko J., Benner A., Döhner H., et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997, 20:399-407.
38. Seto M. Genomic profiles in B cell lymphoma. Int J Hematol 2010, 92:238-245.
39. Duyster J., Bai R.Y., Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001, 20:5623-5637.
40. Liang X., Meech S.J., Odom L.F., Bitter M.A., Ryder J.W., Hunger S.P., et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol 2004, 121:496-506.
41. Kelleher F.C., McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 2010, 46:2357-2368.
42. Granowetter L. Ewing's sarcoma and extracranial primitive neuroectodermal tumors. Curr Opin Oncol 1996, 8:305-310.
43. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet 2000, 123:1-26.
44. Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 2007, 117:2036-2043.
45. Sanford M., Scott L.J. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. Drugs 2010, 70:1963-1972.
46. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
47. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
48. Cools J., Wlodarska I., Somers R., Mentens N., Pedeutour F., Maes B., et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002, 34:354-362.
49. Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Dal Cin P., Pinkus J.L., et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157:377-384.
50. Miettinen M. From morphological to molecular diagnosis of soft tissue tumors. New trends in cancer for the 21st century 2006, 99-113. Springer, New York. A. Llombart-Bosch, V. Felipo, J.A. López-Guerrero (Eds.).
51. Bridge J.A., Kanamori M., Ma Z., Pickering D., Hill D.A., Lydiatt W., et al. Fusion of the ALK gene to the clathrin heavy chain gene, CTLC, in inflammatory myofibroblastic tumor. Am J Pathol 2001, 159:411-415.
52. Rosati R., La Starza R., Luciano L., Gorello P., Matteucci C., Pierini V., et al. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia 2006, 20:1623-1624.
53. Metzgeroth G., Walz C., Score J., Siebert R., Schnittger S., Haferlach C., et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21:1183-1188.
54. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways. Proc Natl Acad Sci U S A 1996, 93:14845-14850.
55. Garcia J.L., Font de Mora J., Hernandez J.M., Queizan J.A., Gutierrez N.C., Hernandez J.M., et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 2003, 102:2699-2700.
56. David M., Cross N.C.P., Burgstaller S., Chase A., Curtis C., Dang R., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64.
57. Kurian A.W. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010, 22:72-78.
58. Teixeira M.R. Recurrent fusion oncogenes in carcinomas. Crit Rev Oncogenesis 2006, 12:257-271.
59. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, World Health Organization; Lyon: IARC Press, Geneva. 4th ed.
60. Goldman J.M. Chronic myeloid leukemia: a historical perspective. Semin Hematol 2010, 47:302-311.
61. Agrawal M., Garg R.J., Cortes J., Quintás-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010, 5:70-80.
62. Motyckova G., Stone R.M. The role of molecular tests in acute myelogenous leukemia treatment decisions. Curr Hematol Malig Rep 2010, 5:109-117.
63. Sandberg A.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma. Cancer Genet Cytogenet 2004, 150:93-115.
64. Sandberg A.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004, 155:1-24.
65. Sandberg A.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet 2005, 158:1-26.
66. Sandberg A.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet 2005, 161:1-19.
67. Lones M.A., Heerema N.A., Le Beau M.M., Perkins S.L., Kadin M.E., Kjeldsberg C.R., et al. Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet 2006, 171:89-96.
68. Stenman G. Fusion oncogenes and tumor type specificity: insights from salivary gland tumors. Semin Cancer Biol 2005, 15:224-235.
69. Voz M.L., Van de Ven W.J.M., Kas K. First insights into the molecular basis of pleomorphic salivary glands. Adv Dent Res 2000, 14:81-83.
70. Asp J., Persson F., Kost-Alimova M., Stenman G. CHCHD7-PLAG1 and TCEA1-PLAG1 gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas. Genes Chromosomes Cancer 2006, 45:820-828.
71. Cleynen I., Van de Ven W.J. The HMGA proteins: a myriad of functions. Int Oncol 2008, 32:289-305. (Review).
72. Young A.R., Narita M. Oncogenic HMGA2: short or small?. Genes Dev 2007, 21:1005-1009.
73. Geurts J.M., Schoenmakers E.F., Röijer E., Aström A.K., Stenman G., van de Ven W.J. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 1998, 16:865-872.
74. Bullerdiek J., Haubrich J., Meyer K., Bartnitzke S. Translocation t(11;19)(q21;p13.1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin's tumor) of the parotid gland. Cancer Genet Cytogenet 1988, 35:129-132.
75. Tirado Y., Williams M.D., Hanna E.Y., Kaye F.J., Batsakis J.G., El-Naggar A.K. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer 2007, 46:708-715.
76. Fehr A., Röser K., Belge G., Löning T., Bullerdiek J. A closer look at Warthin tumors with respect to the t(11;19). Cancer Genet Cytogenet 2008, 180:135-139.
77. Enlund F., Behboudi A., Andrén Y., Oberg C., Lendahl U., Mark J., et al. Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors. Exp Cell Res 2004, 292:21-28.
78. Martins C., Cavaco B., Tonon G., Kaye F.J., Soares J., Fonseca I. A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands. J Mol Diagn 2004, 6:205-210.
79. Behboudi A., Enlund F., Winnes M., Andrén Y., Nordkvist A., Leivo I., et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 2006, 45:470-481.
80. El-Naggar A.K., Lovell M., Killary A.M., Clayman G.L., Batsakis J.G. A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. Cancer Genet Cytogenet 1996, 87:29-33.
81. Behboudi A., Winnes M., Gorunova L., van den Oord J.J., Mertens F., Enlund F., et al. Clear cell hidradenoma of the skin: a third tumor type with a t(11;19)-associated TORC1-MAML2 gene fusion. Genes Chromosomes Cancer 2005, 43:202-205.
82. Tonon G., Gehlhaus K.S., Yonescu R., Kaye F.J., Kirsch I.R. Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas. Cancer Genet Cytogenet 2004, 152:15-22.
83. Wu L., Liu J., Gao P., Nakamura M., Cao Y., Shen H., et al. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J 2005, 24:2391-2402.
84. Coxon A., Rozenblum E., Park Y.S., Joshi N., Tsurutani J., Dennis P.A., et al. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res 2005, 65:7137-7144.
85. Queimado L., Lopes C.S., Reis A.M.C. WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors. Genes Chromosomes Cancer 2007, 46:215-225.
86. Freier K., Flechtenmacher C., Walch A., Ohl S., Devens F., Burke B., et al. Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis. Cancer Genet Cytogenet 2005, 159:89-95.
87. Martins C., Fonseca I., Roque L., Ribeiro C., Soares J. Cytogenetic similarities between two types of salivary gland carcinomas: adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Cancer Genet Cytogenet 2001, 128:130-136.
88. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
89. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66:3396-3400.
90. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006, 45:717-719.
91. Wang J., Cai Y., Ren C., Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006, 66:8347-8351.
92. Yoshimoto M., Joshua A.M., Chilton-MacNeill S., Bayani J., Selvarajah S., Evans A.J., et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006, 8:465-469.
93. Yoshimoto M., Ludkovski O., Bayani J., Graham C., Zielenska M., Squire J.A. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 2007, 46:861-863.
94. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., Henrique R., Jerónimo C., et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8:826-832.
95. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66:8337-8341.
96. Liu W., Ewing C.M., Chang B.L., Li T., Sun J., Turner A.R., et al. Multiple genomic alterations on 21q22 predict various TMPRSS2-ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 2007, 46:972-980.
97. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
98. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006, 66:10242-10246.
99. Tu J.J., Rohan S., Kao J., Kitabayashi N., Mathew S., Chen Y.T. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007, 20:921-928.
100. Mehra R., Han B., Tomlins S.A., Wang L., Menon A., Wasco M.J., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007, 67:7991-7995.
101. Qin H.R., Iliopoulos D., Semba S., Fabbri M., Druck T., Volinia S., et al. A role for the WWOX gene in prostate cancer. Cancer Res 2006, 66:6477-6481.
102. Yoshimoto M., Cunha I.W., Coudry R.A., Fonseca F.P., Torres C.H., Soares F.A., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685.
103. Zhang H., Wang J., Pang B., Liang R., Li S., Huang P., et al. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res 2007, 67:8906-8913.
104. Kim J.H., Dhanasekaran S.M., Mehra R., Tomlins S.A., Gu W., Yu J., et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007, 67:8229-8239.
105. Yu J., Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007, 67:10657-10663.
106. Lapointe J., Li C., Giacomini C.P., Salari K., Huang S., Wang P., et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007, 67:8504-8510.
107. Rajput A.B., Miller M.A., De Luca A., Boyd N., Leung S., Hurtado-Coll A., et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007, 60:1238-1243.
108. Demichelis F., Rubin M.A. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 2007, 60:1185-1186.
109. Mehra R., Tomlins S.A., Shen R., Nadeem O., Wang L., Wei J.T., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007, 20:538-544.
110. Perner S., Mosquera J.M., Demichelis F., Hofer M.D., Paris P.L., Simko J., et al. TMPRSS2-ETS fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007, 31:882-888.
111. Saini S., Majid S., Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res 2010, 27:1014-1026.
112. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
113. Makretsov N., He M., Hayes M., Chia S., Horsman D.E., Sorensen P.H., et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004, 40:152-157.
114. Knezevich S.R., McFadden D.E., Tao W., Lim J.F., Sorensen P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998, 18:184-187.
115. Rubin B.P., Chen C.J., Morgan T.W., Xiao S., Grier H.E., Kozakewich H.P., et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998, 153:1451-1458.
116. Skálová A., Vanecek T., Sima R., Laco J., Weinreb I., Perez-Ordonez B., et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010, 34:599-608.
117. Eguchi M., Eguchi-Ishimae M., Tojo A., Morishita K., Suzuki K., Sato Y., et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999, 93:1355-1363.
118. Takahashi T., Watanabe M., Minato M., Yoshimoto M., Tsujisaki M. A novel t(12;15)(q22;q13) in a patient with acute monoblastic leukemia. Cancer Genet Cytogenet 2007, 177:164-165.
119. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: congenital (infantile) fibrosarcoma and mesoblastic nephroma. Cancer Genet Cytogenet 2002, 132:1-13.
120. Yin C.C., Medeiros L.J., Bueso-Ramos C.E. Recent advances in the diagnosis and classification of myeloid neoplasms: comments on the 2008 WHO classification. Int J Lab Hematol 2010, 32:461-476.
121. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061. [Erratum in: Lancet 2005;366:122].
122. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005, 434:1144-1148.
123. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J.P., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
124. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
125. Dai Y. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat 2010, 20:885-897.
126. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
127. Nussenzveig R.H., Swierczek S.I., Jelinek J., Gaikwad A., Liu E., Verstovsek S., et al. Polycythemia vera is not initiated by the JAK2V617F mutation. Exp Hematol 2007, 35:32-38.
128. Lemas M.V., Ambinder R.F. Does JAK2 1849G>T initiate polycythemia vera?. Blood 2006, 108:8-9.
129. Kralovics R., Teo S.S., Li S., Theocharides A., Buser A.S., Tichelli A., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108:1377-1380.
130. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373.
131. Fröhling S., Lipka D.B., Kayser S., Scholl C., Schlenk R.F., Döhner H., et al. Rare occurrence of the JAK2 V617F mutation in AMF subtypes M5, M6, and M7. Blood 2006, 107:1242-1243.
132. Theocharides A., Boissinot M., Girodon F., Garand R., Teo S.S., Lippert E., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375-379.
133. Hélias C., Struski S., Gervais C., Leymarie V., Mauvieux L., Herbrecht R., et al. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK, and SMARCA2. Cancer Genet Cytogenet 2008, 180:51-55.
134. Ohyashiki K., Hori K., Makino T., Ohyashiki J.H. Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. Cancer Genet Cytogenet 2007, 179:19-24.
135. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846. Italian Group for Malignant Hematologic Disorders of the Adult-Myeloproliferative Disorder Working Party (GIMEMA-MPD WP).
136. Campbell P.J., Griesshammer M., Döhner K., Döhner H., Kusec R., Hasselbalch H.C., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006, 107:2098-2100.
137. Ishii T., Bruno E., Hoffman R., Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006, 108:3128-3134.
138. Levine R.L., Loriaux M., Huntly B.J.P., Loh M.L., Beran M., Stoffregen E., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106:3377-3379.
139. Campbell P.J., Baxter E.J., Baer P.A., Scott L.M., Bench A.J., Huntly B.J.P., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemia transformation. Blood 2006, 108:3548-3555.
140. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006, 107:4214-4222.
141. Tefferi A. JAK2 mutations in polycythemia vera: molecular mechanisms and clinical applications. N Engl J Med 2007, 356:444-445.
142. Norton A., Fisher C., Liu H., Wen Q., Mundschau G., Fuster J.L., et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 2007, 110:1077-1079.
143. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
144. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
145. Park T.S., Song J., Kim J.S., Yang W.I., Song S., Kim S.J., et al. 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33) CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. Cancer Genet Cytogenet 2008, 181:93-99.
146. Grady W.M., Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010, 59:706-708.
147. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010, 10:297-308.
148. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587.
149. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
150. Wu W., Sun M., Zou G.M., Chen J. MicroRNA and cancer: current status and prospective. Int J Cancer 2007, 120:953-960.
151. Esquela-Kerscher A., Slack F.J. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
152. Wijnhoven B.P.L., Michael M.Z., Watson D.I. MicroRNAs and cancer. Br J Surg 2007, 94:23-30.
153. Tricoli J.V., Jacobson J.W. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res 2007, 67:4553-4555.
154. Calin G.A., Croce C.M. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007, 117:2059-2066.
155. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12.
156. Zhang W., Dahlberg J.E., Tam W. MicroRNAs in tumorigenesis: a primer. Am J Pathol 2007, 171:728-738.
157. Kearney L., Tosi S., Jaju R.J. Detection of chromosome abnormalities in leukemia using fluorescence in situ hybridization. Methods Mol Med 2002, 68:7-27.
158. Hilgenfeld E., Montagna C., Padilla-Nash H., Stapleton L., Heselmeyer-Haddad K., Ried T. Spectral karyotyping in cancer cytogenetics. Methods Mol Med 2002, 68:29-44.
159. Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007, 13:4960-4963.
160. Ibbotson R.E., Corcoran M.M. Detection of chromosomal deletions by microsatellite analysis. Methods Mol Med 2002, 68:59-65.
161. Kong C.F., Bowtell D. Genomewide gene expression analysis using cDNA microarrays. Methods Mol Med 2002, 68:195-204.
162. Duesberg P. Chromosomal chaos and cancer. Sci Am 2007, 296:52-59.
163. Fabarius A., Li R., Yerganian G., Hehlmann R., Duesberg P. Specific clones of spontaneously evolving karyotypes generate the individuality of cancer. Cancer Genet Cytogenet 2008, 180:89-99.
164. Shivaswamy S., Bhinge A., Zhao Y., Jones S., Hirst M., Iyer V.R. Dynamic remodeling of individual nucleosomes across a eukaryotic genome in response to transcriptional perturbation. PLoS Biol 2008, 6:e65.
165. Khan J., Saal L.H., Bittner M.L., Jiang Y., Gooden G.C., Glatfelter A.A., et al. Gene expression profiling in cancer using cDNA microarrays. Methods Mol Med 2002, 68:205-222.